Vasorelaxing effects of propranolol in rat aorta and mesenteric artery: A role for nitric oxide and calcium entry blockade

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 5-6, 2006, Pages 448-455

  Priviero, Fernanda B M ^a   Teixeira, Cleber E ^b   Toque, Haroldo A F ^a   Claudino, Mário A ^a   Webb, R Clinton ^b   De Nucci, Gilberto ^a   Zanesco, Angelina ^c   Antunes, Edson ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Blood vessels; Calcium blockade; Endothelium; Propranolol; Relaxation

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ATENOLOL; BETA ADRENERGIC RECEPTOR; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHLORIDE; CYCLIC GMP; GUANYLATE CYCLASE INHIBITOR; INDOMETACIN; METOPROLOL; N(G) NITROARGININE METHYL ESTER; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PHORBOL DIBUTYRATE; PROPRANOLOL;

ANIMAL TISSUE; AORTA; ARTERY MUSCLE; ARTICLE; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; ENDOTHELIUM; ISOMER; MALE; MESENTERIC ARTERY; MUSCLE CONTRACTION; NONHUMAN; RACEMIC MIXTURE; RAT; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SOLUTION AND SOLUBILITY; TISSUE REACTION; UPREGULATION; VASODILATATION;

ANIMALS; AORTA; CALCIUM; CALCIUM CHANNEL BLOCKERS; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GUANYLATE CYCLASE; MALE; MESENTERIC ARTERIES; MUSCLE, SMOOTH, VASCULAR; NG-NITROARGININE METHYL ESTER; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXADIAZOLES; PROPRANOLOL; QUINOXALINES; RATS; VASODILATION; VASODILATOR AGENTS;

EID: 33745220325     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04386.x     Document Type: Article

References (43)

1. Struthers AD, Dollery CT. Central nervous system mechanisms in blood pressure control. Eur. J. Clin. Pharmacol. 1985, 28 3 11.
2. Yan AT, Yan RT, Liu PP. Narrative review. Pharmacotherapy for chronic heart failure: Evidence from recent clinical trials. Ann. Intern. Med. 2005 142 : 32 45.
3. Daugherty A, Frayn KN, Redfern WS, Woodward B. The role of catecholamines in the production of ischaemia-induced ventricular arrhythmias in the rat in vivo and in vitro. Br. J. Pharmacol. 1986 87 : 265 77.
4. Marano G, Palazzesi S, Fadda A, Vergari A, Ferrari AU. Attenuation of aortic banding-induced cardiac hypertrophy by propranolol is independent of beta-adrenoceptor blockade. J. Hypertens. 2002 20 : 763 9.
5. 1-adrenoceptor blocking activity of (+)- and (-)-propranolol on the rat left atria. Gen. Pharmacol. 1999 21 : 677 80.
6. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998 98 : 1184 91.
7. Grassi G. Counteracting the sympathetic nervous system in essential hypertension. Curr. Opin. Nephrol. Hypertens. 2004 13 : 513 19.
8. Rajfer IS, Kohli JD, Goldberg LI. Contractile actions of racemic and d-propranolol on isolated canine mesenteric and coronary arteries. J. Pharmacol. Exp. Ther. 1982 220 : 127 32.
9. Kalsner S. Propranolol antagonizes coronary artery relaxation by a potassium channel opener. Life Sci. 1994 55 : 1109 21.
10. Van Den Meiracker AH, Man In't Veld AJ, Boomsma F, Fischberg DJ, Molinoff PB, Schalekamp MA. Hemodynamic and β-adrenergic receptor adaptations during long-term β-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. Circulation 1998 80 : 903 14.
11. Mostaghim R, Maddox YT, Ramwell PW. Endothelial potentiation of relaxation response to beta adrenoceptor blocking agents. J. Pharmacol. Exp. Ther. 1986 239 : 797 801.
12. Gao YS, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J. Cardiovasc. Pharmacol. 1991 17 : 964 9.
13. Kurosaki K, Ikeda U, Maeda Y, Shimada K. Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes. J. Mol. Cell. Cardiol. 2000 32 : 333 9.
14. Broeders MA, Doevendans PA, Bekkers BC et al. Nebivolol: A third-generation beta-blocker that augments vascular nitric oxide release: Endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 2000 102 : 677 84.
15. Arumanayagam M, Chan S, Tong S, Sanderson JE. Antioxidant properties of carvedilol and metoprolol in heart failure: A double-blind randomized controlled trial. J. Cardiovasc. Pharmacol. 2001 37 : 48 54.
16. Hirawa N, Uehara Y, Numabe A et al. Inhibitory effects of beta adrenoceptor antagonist, atenolol, on the thromboxane system in the kidney of spontaneously hypertensive rats. Prostaglandins Leukot. Essent. Fatty Acids 1991 43 : 93 8.
17. Kahönen M, Makynen H, Arvola P, Porsti I. Enhancement of arterial relaxation by long-term atenolol treatment in spontaneously hypertensive rats. Br. J. Pharmacol. 1994 112 : 925 33.
18. Pacca SR, de Azevedo AP, De Oliveira CF, De Luca IM, De Nucci G, Antunes E. Attenuation of hypertension, cardiomyocyte hypertrophy, and myocardial fibrosis by beta-adrenoceptor blockers in rats under long-term blockade of nitric oxide synthesis. J. Cardiovasc. Pharmacol. 2002 39 : 201 7.
19. Greenberg B. Nonselective versus selective beta-blockers in the management of chronic heart failure: Clinical implications of the carvedilol or Metoprolol European Trial. Rev. Cardiovasc. Med. 2004 5 ( Suppl. 1 S10 17.
20. Abraham WT, Iyengar S. Practical considerations for switching beta-blockers in heart failure patients. Rev. Cardiovasc. Med. 2004 5 ( Suppl. 1 S36 44.
21. Puddu P, Puddu GM, Cravero E, Muscari A. Different effects of antihypertensive drugs on endothelial dysfunction. Acta Cardiol. 2004 59 : 555 64.
22. Rokutanda M, Araki S, Sakanashi M. A pharmacological investigation on a possible calcium antagonistic action of propranolol. Arch. Int. Pharmacodyn. Ther. 1983 262 : 99 108.
23. Sakanashi M, Takeo S. Characterization of propranolol-induced relaxation of coronary artery. Jpn. J. Pharmacol. 1983 33 : 603 10.
24. Maia ER, Villacorta H, Subietta CG, Munhoz C, Romeo Filho LJ, Mesquita ET. Use of propranolol in heart failure patients: Safety, tolerability, and effects on left ventricular function. Rev. Port. Cardiol. 2001 20 : 383 99.
25. 2+-permeable non-selective cation channels in smooth muscle cells. Cell Calcium 2003 33 : 345 56.
26. 2+ release and entry during contraction elicited by norepinephrine in rat resistance arteries. Am. J. Physiol. 1999 276 : H300 8.
27. Weiner N. Drugs that inhibit adrenergic nerves and block adrenergic receptors. In : Gilman AG, Goodman LS, Gilman A (eds). The Pharmacological Basis of Therapeutics, 6th edn. McMillan, New York. 1980 176 210.
28. Barrett AM, Cullum VA. Lack of interaction between propranolol and mebanazine. J. Pharm. Pharmacol. 1968 20 : 911 15.
29. Mehvar R, Brocks DR. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J. Pharm. Pharm. Sci. 2001 4 : 185 200.
30. Gardiner SM, Compton AM, Bennett T, Palmer RM, Moncada S. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990 15 : 486 92.
31. Uchida W, Shibasaki K, Asano M, Takenaka T. Antianginal effects of YM-16151-4 in various experimental angina models. J. Cardiovasc. Pharmacol. 1993 21 : 701 8.
32. Hayashi T, Yamada K, Esaki T, Muto E, Iguchi A. The beta adrenoreceptor antagonist, nipradilol, preserves the endothelial nitric oxide response in atherosclerotic vessels of rabbit. Life Sci. 1997 61 : 1379 87.
33. Noda K, Oka M, Ma FH, Kitazawa S, Ukai Y, Toda N. Release of endothelial nitric oxide in coronary arteries by celiprolol, a beta(1)-adrenoceptor antagonist: Possible clinical relevance. Eur. J. Pharmacol. 2001 415 : 209 16.
34. Ignarro LJ, Byrns RE, Trinh K, Sisodia M, Buga GM. Nebivolol: A selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide 2002 7 : 75 82.
35. Mak IT, Weglicki WB. Protective effect of β-blocking agents against free radical-mediated sarcolemmal lipid peroxidation. Circ. Res. 1988 63 : 262 6.
36. Khaper N, Rigatto C, Seneviratne C, Li T, Singal PK. Chronic treatment with propranolol induces antioxidant changes and protects against ischemia-reperfusion injury. J. Mol. Cell. Cardiol. 1997 29 : 3335 44.
37. Kenakin TP. Pharmacologic Analysis of Drug-Receptor Interaction, 2nd edn. Raven Press, New York. 1993.
38. Smith WL. Prostaglandin biosynthesis and its compartmentation in vascular smooth muscle and endothelial cells. Annu. Rev. Physiol. 1986 48 : 251 62.
39. Webb RC. Smooth muscle contraction and relaxation. Adv. Physiol. Educ. 2003 27 : 201 6.
40. Wu X, Somlyo AV, Somlyo AP. Cyclic GMP-dependent stimulation reverses G-protein-coupled inhibition of smooth muscle myosin light chain phosphate. Biochem. Biophys. Res. Commun. 1996 220 : 658 63.
41. 2+ desensitization in vascular smooth muscle by activating the myosin light chain phosphatase. J. Biol. Chem. 1997 272 : 5063 8.
42. 2+ entry and the regulation of smooth muscle tone. Trends Pharmacol. Sci. 1998 19 : 266 9.
43. Kwan CY, Chaudhary R, Zheng XF, Ni J, Lee RM. Effects of sarcoplasmic reticulum calcium pump inhibitors on vascular smooth muscle. Hypertension 1994 23 ( Suppl. 1 I156 60.